#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

High-Dose Rate Brachyther­apy in the Treatment of Early Stages of Penile Carcinoma


Authors: D. Pohanková 1;  I. Sirák 1;  L. Kašaová 1;  J. Grepl 1;  P. Paluska 1;  M. Louda 2;  L. Holub 2;  J. Špaček 2;  P. Prošvic 3;  J. Petera 1
Authors‘ workplace: Klinika onkologie a radioterapie LF UK a FN Hradec Králové 1;  Urologická klinika LF UK a FN Hradec Králové 2;  Urologické oddělení, Oblastní nemocnice Náchod 3
Published in: Klin Onkol 2019; 32(1): 52-57
Category: Original Articles
doi: https://doi.org/10.14735/amko201952

Overview

Background:

Interstitial low dose rate brachyther­apy is established organ spar­ing treatment of T1–T2 penile carcinoma. Experience with high-dose rate brachyther­apy is limited in this indication.

Materials and methods:

Twenty-six patients with early penile carcinoma were treated by high-dose rate brachyther­apy at dose 18 × 3 Gy per fraction twice daily between 2002–2018 at the Department of Oncology and Radiother­apy, University Hospital in Hradec Kralove. Breast interstitial brachyther­apy template was used for fixation and precise geometry reconstruction of stainless hollow needles.

Results:

Median follow up was 85 months (range 7–200 months). Acute reaction usually consisted of grade 2 mucositis that dissolved dur­ing 8 weeks after the treatment. Local recurrence occurred in 6 patients, 5 of them were successfully treated with partial amputation. One patient had a nodal recurrence successfully salvaged by lymphadenectomy. One patient developed necrosis of the glans requir­ing partial amputation. Currently, there are 24 patients alive without signs of dis­ease. One patient died of cardiac comorbidity, one died of duplicate lung cancer. Nineteen patients have a preserved penis (73%), 18 of them sexually active before treatment report satisfactory intercourse.

Conclusion:

Hyperfractionated interstitial high-dose rate brachyther­apy with 18 × 3 Gy per fraction twice daily is a promis­ing method in selected patients with penile carcinoma and deserves further evaluation in a larger prospective study.

Key words

penile neoplasms – conservative treatment – brachyther­apy

This work was supported by programm Progres Q40.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 8. 1. 2019

Accepted: 15. 1. 2019


Sources

1. Siegel RL, Mil­ler KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1): 7–30. doi: 10.3322/caac.21387.

2. Korzeniowski MA, Crook JM. Contemporary role of radiother­apy in the management of penile cancer. Transl Androl Urol 2017; 6(5): 855–867. doi: 10.21037/tau.2017.07.02.

3. Mor­rison BF. Risk factors and prevalence of penile cancer. West Indian Med J 2014; 63(6): 559–560. doi: 10.7727/wimj.2015.381.

4. Novotvary 2016. Cancer Incidence in the Czech Republic. Praha: ÚZIS ČR 2016.

5. Schoen EJ. The relationship between circumcision and cancer of penis. CA Cancer J Clin 1991; 41(5): 306–309.

6. Uroweb.org. Penile cancer. European As­sociation of Urology. [online]. Available from: https://uroweb.org/guideline/penile-cancer/.

7. Hasan S, Francis A, Hagenauer A et al. The role of brachyther­apy in organ preservation for penile cancer: a meta-analysis and review of the literature. Brachyther­apy 2015; 14(4): 517–524. doi: 10.1016/j.brachy.2015.03.008.

8. Azrif M, Logue JP, Swindell R et al. External-beam radiother­apy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol) 2006; 18(4): 320–325.

9. De Crevosier R, Slimane K, Sanfilippo N et al. Long-term results of brachyther­apy for carcinoma of penile confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 2009; 74(4): 1150–1156. doi: 10.1016/j.ijrobp.2008.09.054.

10. Crook J, Ma C, Grimard L. Radiation ther­apy in the management of the primary penile tumor: an update. World J Urol 2009; 27(2): 189–196. doi: 10.1007/s00345-008-0309-5.

11. Chaudhary AJ, Ghosh S, Bhalavat RL et al. Interstitial brachyther­apy in carcinoma of the penis. Strahlenther Onkol 1999; 175(1): 17–20.

12. Gerbaulet A, Lambin P, Haie-Meder C. Brachyther­apy in cancer of the penis. Ann Urol (Paris) 1994; 28(6–7): 206–311.

13. Petera J, Sirák I, Kašaová L et al. High-dose rate brachyther­apy in the treatement of penile carcinoma – first experience. Brachyther­apy 2011; 10(2): 136–140. doi: 10.1016/j.brachy.2010.05.007.

14. Delan­nes M, Malavaud B, Douchez J et al. Iridium-192 interstitial ther­apy for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 1992; 24(3): 479–483.

15. Kiltie AE, Elwell C, Close HJ et al. Iridium-192 implantation for node-negative carcinoma of the penis: the Cookridge Hospital experience. Clin Oncol (R Coll Radiol) 2000; 12(1): 25–31.

16. Rozan R, Albuis­son E, Giraud B et al. Interstitial brachyther­apy for penis carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995; 36(2): 83–93.

17. Soria JC, Fizazi K, Piron D et al. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol 1997; 8(11): 1089–1098.

18. Yamazaki H, Inoue T, Yoshida K et al. Brachyther­apy for early tongue cancer: low dose rate to high dose rate. J Radiat Res 2003; 44(1): 37–40.

19. Strnad V, Ott OJ, Hildebrandt G et al. 5-year result of accelerated partial breast ir­radiation us­­ing sole interstitial multicatheter brachyther­apy versus whole-breast ir­radiation with boost after breast–conserv­­ing surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387(10015): 229–238. doi: 10.1016/S0140-6736(15)00471-7.

20. Scopus-com. Soumarova R, Homola L, Perkova H et al. Interstitial HDR boost in the treatment of localized prostate carcinoma – our results. [online]. Available from: https://www-scopus-com.ezproxy.is.cuni.cz/record/display.uri.

21. Petera J, Dolezel M, Jirousek Z et al. High dose rate brachyther­apy in the treatment of oral cancer – the preliminary one institution experience. Neoplasma 2006; 53(3): 232–236.

22. Petera J, Soumarova R, Ruzickova J et al. Perioperative hyperfractionated high-dose rate brachyther­apy for the treatment of soft tis­sue sarcomas: multicentric experience. Ann Surg Oncol 2010; 17(1): 206–210. doi: 10.1245/s10434-009-0684-1.

23. Mazeron JJ, Langois D, Lobo PA et al. Interstitial radiation ther­apy for carcinoma of the penis us­­ing iridium 192 wires: the Hanri Mondor experience (1970–1979). Int J Radiat Oncol Biol Phys 1984; 10(10): 1891–1895.

24. Escande A, Haie-Meder C, Mazeron R et al. Brachyther­apy for conservative treatment of invasive penile carcinoma: prognostic factors and long-term analysis of outcome. Int J Radiat Oncolo Biol Phys 2016; 99(3): 563–570. doi: 10.1016/j.ijrobp.2017.02.090.

25. Crook JM, Haie-Meder C, Desmanes DJ et al. American Brachyther­apy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachyther­apy. Brachyther­apy 2013; 12(3): 191–198. doi: 10.1016/j.brachy.2013.01.167.

26. Sharma DN, Joshi NP, Gandhi AK et al. High dose rate interstitial brachyther­apy for T1–T2 stage penile carcinoma: short-term results. Brachyther­apy 2014; 13(5): 481–487. doi: 10.1016/j.brachy.2014.06.003.

27. Rouscoff Y, Falk AT, Durand M et al. High-dose rate brachyther­apy in localized penile cancer: short-term clinical outcome analysis. Radiat Oncol 2014; 9: 142. doi: 10.1186/1748-717X-9-142.

28. Doležalová H, Blechová N, Petera J. Kvalita života pa­cientů s časnými nádory dutiny ústní léčených pooperační brachyterapií s vysokým dávkovým příkonem pro těsné nebo pozitivní okraje. Klin Onkol 2018; 31(2): 125–129. doi: 10.14735/amko2018125.

Labels
Paediatric clinical oncology Surgery Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#